DGKA could enhance hepatocellular carcinoma progression via Ras-Raf-MEK-ERK pathway and promote platinum resistance by activating c-JUN-WEE1 signaling in ovarian cancer (21, 22). Here, MAP2K7 is linked to ovarian carcinoma.